Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
International Journal of Oncology
Join Editorial Board Propose a Special Issue
Print ISSN: 1019-6439 Online ISSN: 1791-2423
Journal Cover
August-2014 Volume 45 Issue 2

Full Size Image

Cover Legend PDF

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
August-2014 Volume 45 Issue 2

Full Size Image

Cover Legend PDF

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Plastic induction of CD133AC133-positive cells in the microenvironment of glioblastoma spheroids

  • Authors:
    • Ken Ohnishi
    • Toshiaki Tani
    • Shin-Ichi Bando
    • Nobuo Kubota
    • Yoshihiro Fujii
    • Osamu Hatano
    • Hirosi Harada
  • View Affiliations / Copyright

    Affiliations: Department of Biology, Center for Humanity and Sciences, Ibaraki Prefectural University of Health Sciences, Inashiki-gun, Ibaraki 300-0394, Japan, Department of Radiological Sciences, Ibaraki Prefectural University of Health Sciences, Inashiki-gun, Ibaraki 300-0394, Japan, Department of Anatomy, Nara Medical University, Kashihara, Nara 634-8521, Japan, Group of Radiation and Tumor Biology, Career-Path Promotion Unit for Young Life Scientists, Kyoto University, Yoshida-Konoe-Cho, Sakyo-ku 606-8501, Japan
  • Pages: 581-586
    |
    Published online on: June 3, 2014
       https://doi.org/10.3892/ijo.2014.2483
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Recent studies showed that the stemness of cancer stem cells is maintained under a hypoxic microenvironment. However, the relationship of the hypoxic microenvironment in a three-dimensional cell mass and the induction of cancer stem cell-like phenotype is not well known. We examined the relationship between CD133 expression and the hypoxic microenvironment using glioblastoma spheroids formed with the T98G cell line. CD133AC133- and HIF-1α-positive cells were observed in the marginal region of the central hypoxic area positive for HIF-1α 10 days after plating T98G cells. CD133AC133-positive cells were positive for nestin. Quantitative PCR analysis showed that the CD133 expression level is not different in spheroids during the tested period after spheroid formation, indicating that post-translational regulation of the CD133 protein mediates positivity to CD133AC133. When spheroids were trypsinized and the dissociated cells were cultured under the adherent monolayer conditions, the CD133AC133-positive cells gradually disappeared. These results show that CD133AC133-positive cells, which may incline toward undifferentiated cells because of nestin positivity, are plastically induced under the different culture conditions, spheroid and monolayer. In this plasticity, HIF-1α is involved in the induction and maintenance of CD133AC133-positive cells. Spheroids as an in vitro tumor model are useful to study the dynamic changes in the tumor cell phenotype in the different cell microenvironments.

Introduction

Glioblastomas are highly radio- and chemotherapy-resistant cancers, because they contain cellular hierarchies with cancer stem cells (CSCs) that are radio- and chemoresistant (1–4). CSCs are maintained within the niche for stem cells, such as the hypoxic microenvironment (5), as previously shown in normal stem cells (6). Hypoxia contributes to the self-renewal, differentiation, and quiescence of CSCs (7). Hypoxia-inducible factors (HIFs) become stable under the hypoxic condition and transcriptionally upregulate genes that promote cell survival, motility, and tumor angiogenesis, leading to the promotion of cancer cells to a more malignant state. However, the role of HIFs in the maintenance of CSCs is not fully understood. Recent studies have shown that HIFs maintain glioma stem cells via overexpression of ZNF217 (8), promote expansion of glioma stem cells (9), and upregulate the expression of CD133 protein in glioblastoma-derived neurospheres (10). Furthermore, HIFs may mediate the expression of chemoresistance markers in CSCs (11). It has been shown that in glioblastoma-derived neurospheres, hypoxia induces increases in the expression of not only HIFs and CD133 but also chemoresistance-related markers (MGMT, TIMP-1, Lamp-1, MRP1 and MDR-1). Similarly, in cancer cell lines as well as in CSCs, HIFs contribute to the regulation of stemness-related cellular responses such as neurosphere formation (7) and the upregulation of CD133 (12) and the stem cell factors OCT4, NANOG, SOX2, KLF4 and c-MYC (7,13). These findings indicate that the hypoxic condition play an important role in the stemness state of cancer cells as well as CSCs.

CD133 has recently attracted much attention as a marker for identifying CSCs in glioblastoma, hepatic cancer, melanoma, osteosarcoma and colon cancer (14–19). However, the physiological function of the transmembrane protein CD133 remains unknown. On the basis of the assessment of graft survival rate in a xenograft model and ability of sphere formation under the routine culture condition, it was demonstrated that CD133-positive cells exhibit properties of CSCs. In contrast, controversial results indicating that CD133-negative cells also exhibit properties of CSCs have been reported (20–23). A possible explanation for this discrepancy is the plasticity of CD133 expression, which is dependent on the cellular microenvironment. In glioblastoma neurosphere cells, the level of CD133 expression was reported to vary with oxygen concentration (24). In addition, hypoxia-induced CD133 expression has been reported in human lung cancer cell lines (12). It has been reported that in SW620 colorectal cancer cells, CD133 expression changes depending on the type of the microenvironment (25). Under the low-nutrient culture condition, CD133-negative SW620 colorectal cancer cells re-expressed CD133. These results indicate that CD133 expression is dynamic and modulated by the cellular microenvironment. It seems that CD133 is not a critical marker of glioblastoma CSCs. The plasticity of CD133 expression in the non-stem and stem-like glioblastoma populations provides careful consideration about effects of the hypoxic microenvironment on both cell populations.

Spheroids, larger cell masses compared with spheres, can be used as an in vitro tumor model, which exhibits marked similarity to the three-dimensional growth and morphological characteristics of in vivo tumors (26). Cells in the outer region of spheroids are exposed to a normoxic, nutrient-rich, and neutral pH microenvironment, but cells in the central area of spheroids are exposed to a hypoxic, low-nutrient, and low pH microenvironment. Cellular oxygen consumption of V79 and EMT6 spheroid cells decreases ~3-fold with the increase in the size of spheroids (27,28). Such three-dimensional characteristics of spheroids are expected to provide useful information for the behavior of stemness-related markers under a hypoxic microenvironment. In this study, we examined the expression of CD133 using cryostat sections of glioblastoma spheroids formed using the T98G cell line.

Materials and methods

Cell culture

A human glioblastoma cell line (T98G) was maintained in α-minimum essential medium (α-MEM) supplemented with 20 mM 4-(2-hydroxyethyl) piperazine ethane sulfonic acid (HEPES), 8 mM NaHCO3, 50 μg/ml streptomycin, 50 U/ml penicillin and 10% fetal calf serum. T98G cells were cultured in a humidified incubator at 37°C with a mixture of 98% air and 2% CO2.

Spheroid culture

T98G cells were seeded onto non-adherent U-shape bottom 96-well plates (PrimeSurface 96U, MS-9096U, Sumitomo Bakelite Co., Ltd., Tokyo, Japan) in α-MEM at a density of 5,000 or 10,000 cells/well and cultured for 3 days at 37°C with a mixture of 98% air and 2% CO2. Three days later, spheroids were transferred to non-adherent 30-mm dishes (PrimeSurface 35Φ, MS-9035X, Sumitomo Bakelite Co., Ltd.) at a density of 6–10 spheroids/dish to decrease the frequency of medium change during culturing for 7–10 days. The spheroids grew to a diameter of ~300 μm (Fig. 1a).

Figure 1

Spheroids formed using T98G (a) and T98G/5HRE-EGFP (b) transfectants. Images taken with white light (a) and peak excitation wavelength of 488 nm (b) 10 days after seeding of 5,000 cells. Area exhibiting green fluorescence shows the hypoxic area (b).

Preparation of frozen cryostat sections

Spheroids were rinsed with PBS and fixed with 10% formalin containing 10% sucrose for ≥1 h. After rinsing with PBS, spheroids were embedded in Tissue-Tek O.C.T. Compound (Sakura Finetechnical Co., Ltd., Tokyo, Japan) and cut into 10–20-μm-thick frozen sections using a cryostat.

Stable transfection

To monitor tumor hypoxia, a stable reporter-transfectant, T98G/5HRE-EGFP, which expressed GFP in response to hypoxic stress, was isolated. A plasmid, p5HRE-EGFP, into which was inserted a GFP reporter gene under the regulation of an artificial HIF-1α-dependent promoter, 5HRE, was transfected into T98G cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. Cells were trypsinized 24 h after the transfection and replated onto 100-mm dishes in α-MEM containing G418 (200 μg/ml, Sigma Chemical Co., St. Louis, MO, USA) and then incubated at 37°C for 7–10 days to enable colony formation. Colonies were isolated using cloning cylinders. The hypoxic area was monitored by GFP fluorescence in spheroids formed using T98G/5HRE-EGFP transfectants, as shown in Fig. 1b.

Immunofluorescence staining

Cryostat sections were rinsed twice with PBS and incubated with anti-CD133/1 (AC133) monoclonal antibody (Miltenyi Biotechnology, Auburn, CA, USA), anti-HIF-1α polyclonal antibody (Novus Biologicals, Littleton, CO, USA), or anti-nestin polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at 37°C. After the incubation, cells were washed with PBS three times and then incubated with Alexa Fluor 488 anti-rabbit and/or 546 anti-mouse secondary antibodies (Nacalai Tesque, Kyoto, Japan) for 1 h at 37°C. The sections were then washed with PBS, treated with SlowFade Gold antifade regent with DAPI (Invitrogen), and covered with a glass cover slip.

Quantitative PCR analysis

Total RNA was extracted with a RNAiso Plus kit (Takara, Siga, Japan). RNA extracts (1 μg) were treated with DNase to degrade genomic DNA and then reverse transcribed according to the protocol of PrimeScript RT regent kit (Takara). Quantitative PCR was performed with SYBR Premix Ex Taq™ II (Takara) in 25-μl reactions using 1/25 of the cDNA. The following conditions were used for PCR by Thermal Cycler Dice Real Time System II (Takara): one cycle at 95°C for 30 sec and 95°C for 5 sec, 40 cycles at 60°C for 30 sec, and one cycle at 95°C for 30 sec, 60°C for 30 sec, 95°C for 15 sec for dissociation. The sequence-specific primers of CD133 and β-actin were as follows: CD133: 5′-GGA CCCATTGGCATTCTC-3′ (sense) and 5′-CAGGACACA GCATAGAATAATC-3′ (antisense); β-actin: 5′-GGCACCC AGCACAATGAAG-3′ (sense) and 5′-TCATAGTCCGCCTA GAAGCA-3′ (antisense).

For each sample, nonspecific PCR products were checked using dissociation curves. The threshold cycle (Ct) values for gene expression in each sample were normalized by the relative expression of β-actin.

Results

Observation of CD133AC133- and HIF-1α-positive cells in adherent monolayer cells and spheroids

Double immunofluorescence staining with CD133AC133 and HIF-1α antibodies showed that T98G cells under the adherent monolayer culture condition were not positive for either CD133AC133 or HIF-1α (Fig. 2a–c). However, immunofluorescence staining of cryostat sections showed that 10 days after spheroid formation, many CD133AC133- and HIF-1α-positive cells were located mainly in the marginal region of the central area of T98G spheroids positive for HIF-1α (Fig. 2d–f). In addition, a few CD133AC133- and HIF-1α-positive cells were observed in the outer region near the surface of spheroids. Three days after spheroid formation, CD133AC133- and HIF-1α-positive cells were sparsely distributed in the outer region of spheroids (Fig. 3a–c) and were more abundant 5 days after spheroid formation (Fig. 3d–f). At this early stage after spheroid formation, a few CD133AC133- and HIF-1α-positive cells were observed in the central areas of spheroids positive for HIF-1α.

Figure 2

Images of T98G cells cultured under the adherent monolayer condition (a–c), and images of a cryostat section of T98G spheroid 10 days after spheroid formation (d–f). CD133AC133/HIF-1α/DAPI triple staining was performed.

Figure 3

Images of CD133AC133/HIF-1α/DAPI-stained cryostat sections of T98G spheroid 3 days (a–c) and 5 days after spheroid formation (d–f).

Observation of CD133AC133- and nestin-positive cells in adherent monolayer cells and spheroids

T98G cells under the adherent monolayer culture condition were not positive for CD133AC133 or nestin after double immunofluorescence staining with CD133AC133 and nestin antibodies (Fig. 4a–c). However, immunofluorescence staining of cryostat sections showed that CD133AC133- and nestin-positive cells were located mainly in the marginal region of the central area of spheroids positive for HIF-1α 10 days after spheroid formation (Fig. 4d–f). A few CD133AC133- and nestin-positive cells were also observed in the outer region of spheroids.

Figure 4

Images of T98G cells cultured under the adherent monolayer condition (a–c), and images of a cryostat section of T98G spheroid 10 days after spheroid formation (d–f). CD133AC133/nestin/DAPI triple staining was performed.

Observation of CD133AC133- and nestin-positive cells in adherent monolayer cells dissociated from spheroids

T98G spheroids were trypsinized 10 days after spheroid formation, and the dissociated cells were then cultured under the adherent monolayer condition for scheduled periods (2, 4 and 10 days). The monolayer-cultured cells were immunofluorescently stained with CD133AC133 and nestin antibodies. Many CD133AC133- and nestin-positive cells were observed 2 days after culturing under the adherent monolayer culture condition (Fig. 5a–c), but these cells were slightly decreased after 4 days (Fig. 5d–f). After further culture for 6 days, hardly any CD133AC133- or nestin-positive cells were observed in the adherent monolayer cells (Fig. 5g–i).

Figure 5

Images of T98G cells that were dissociated from spheroids and cultured under the monolayer condition. The cells were stained 2 days (a–c), 4 days (d–f), and 10 days (g–i) after monolayer culture. CD133AC133/nestin/DAPI triple staining was performed.

CD133 expression in spheroids

Real-time quantitative PCR analysis was performed to evaluate CD133 expression in spheroids. No significant differences were observed in the relative mRNA level from 1 to 10 days after spheroid formation (Fig. 6).

Figure 6

Real-time PCR analysis of T98G spheroids. Total RNA was extracted from 12 spheroids 1, 2, 3, 7 and 10 days after spheroid formation. Pre indicates the result obtained from monolayer-cultured T98G cells. No significant differences were observed in the relative mRNA level from 1 to 10 days after spheroid formation. Columns and bars indicate mean values and SD, respectively. Significant differences were examined using Student’s t-test.

Discussion

CD133AC133-positive cells were observed in the outer region of spheroids 3 days after spheroid formation. The oxygenic condition of this region was considered to be normoxic, given that the region was HIF-1α-negative. At this early stage of spheroid formation, CD133AC133-positive cells appear to be oxygen-independently induced. At this stage, most CD133AC133-positive cells were HIF-1α-positive. Oxygen-independent stabilization of HIF-1α is likely to mediate the induction of CD133AC133-positive cells. In contrast to this stage, at a late stage ~10 days after spheroid formation, most CD133AC133-positive cells were observed in the marginal region of the central area of spheroids positive for HIF-1α indicating a hypoxic microenvironment. These results suggest that the different microenvironments within spheroids (the normoxic microenvironment in the outer region and the hypoxic microenvironment in the central region) contribute to the induction and maintenance of CD133AC133-positive cells. However, it is unknown whether CD133AC133-positive cells translocate from the normoxic to the hypoxic microenvironment in the spheroid.

The number of CD133AC133-positive cells dramatically varied in accordance with the change in the culture condition between spheroid and monolayer culture. This finding suggests that the positivity to CD133AC133 may be plastic according to the cellular microenvironments such as low oxygen, low nutrients, and low pH. Given that CD133 expression was not affected by the cell culture condition (Fig. 6), the positivity to CD133AC133 may result from a post-translational modification that enables the CD133AC133 antibody to bind to the AC133 epitope. CD133 is probably differentially folded in CD133AC133-positive and CD133AC133-negative cells as a result of differential glycosylation to mask specific epitopes. Such a post-translational modification of the AC133 epitope has been reported elsewhere in association with the differentiation of CD133AC133-positive cells (29). However, it should be kept in mind that the change in CD133 expression might not be detected by the present quantitative PCR analysis because of low number of CD133AC133-positive cells.

CD133AC133-positive cells in spheroids were also nestin-positive. Because nestin is known to be a marker for undifferentiated neural cells, it has been suggested that the CD133AC133-positive cells may be undifferentiated neural cell-like cells. This finding proposes the possibility that CD133 is not only restricted to CSCs but is also expressed on cancer cells that began to express an undifferentiated phenotype. Tumor cells are exposed to a wide range of microenvironments (low oxygen, low nutrients, and low pH), and these microenvironments may strongly affect the phenotypic expression of their malignant properties.

The present study demonstrated that CD133AC133-positive cells are plastically induced under the different culture conditions, spheroid and monolayer, in relation to stability of HIF-1α. Spheroids as an in vitro tumor model are useful to study the dynamic changes in the tumor cell phenotype in the different cell microenvironments.

Acknowledgements

This study was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References

1 

Bao S, Wu Q, McLendon RE, Hao Y, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI

2 

Mannino M and Chalmers AJ: Radioresistance of glioma stem cells: intrinsic characteristic or property of the ‘microenvironment-stem cell unit’? Mol Oncol. 5:374–386. 2011.

3 

Liu G, Yuan X, Zeng Z, et al: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI

4 

Kang MK and Kang SK: Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev. 16:837–847. 2007. View Article : Google Scholar : PubMed/NCBI

5 

Mohyeldin A, Garzón-Muvdi T and Quiñones-Hinojosa A: Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell. 7:150–161. 2010. View Article : Google Scholar : PubMed/NCBI

6 

Parmar K, Mauch P, Vergilio JA, et al: Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA. 104:5431–5436. 2007. View Article : Google Scholar : PubMed/NCBI

7 

Heddleston JM, Li Z, McLendon RE, et al: The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 8:3274–3284. 2009. View Article : Google Scholar : PubMed/NCBI

8 

Mao XG, Yan M, Xue XY, et al: Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors. Lab Invest. 91:1068–1078. 2011. View Article : Google Scholar : PubMed/NCBI

9 

Soeda A, Park M, Lee D, et al: Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene. 28:3949–3959. 2009. View Article : Google Scholar : PubMed/NCBI

10 

Bar EE, Lin A, Mahairaki V, et al: Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol. 177:1491–1502. 2010. View Article : Google Scholar : PubMed/NCBI

11 

Kolenda J, Jensen SS, Aaberg-Jessen C, et al: Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J Neurooncol. 103:43–58. 2011. View Article : Google Scholar : PubMed/NCBI

12 

Iida H, Suzuki M, Goitsuka R, et al: Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Int J Oncol. 40:71–79. 2012.PubMed/NCBI

13 

Mathieu J, Zhang Z, Zhou W, et al: HIF induces human embryonic stem cell markers in cancer cells. Cancer Res. 71:4640–4652. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Monzani E, Facchetti F, Galmozzi E, et al: Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 43:935–946. 2007. View Article : Google Scholar : PubMed/NCBI

15 

O’Brien CA, Pollett A, Gallinger S, et al: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 445:106–110. 2007.PubMed/NCBI

16 

Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature. 445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI

17 

Ma S, Chan KW, Hu L, et al: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 132:2542–2556. 2007. View Article : Google Scholar : PubMed/NCBI

18 

Tirino V, Desiderio V, Paino F, et al: Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J. 25:2022–2030. 2011. View Article : Google Scholar : PubMed/NCBI

19 

Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature. 432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI

20 

Beier D, Hau P, Proescholdt M, et al: CD133(+) and CD133(−) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 67:4010–4015. 2007.

21 

Joo KM, Kim SY, Jin X, et al: Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest. 88:808–815. 2008. View Article : Google Scholar : PubMed/NCBI

22 

Ogden AT, Waziri AE, Lochhead RA, et al: Identification of A2B5+CD133− tumor-initiating cells in adult human gliomas. Neurosurgery. 62:505–514. 2008.

23 

Wang J, Sakariassen P, Tsinkalovsky O, et al: CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer. 122:761–768. 2008. View Article : Google Scholar : PubMed/NCBI

24 

Platet N, Liu SY, Atifi ME, et al: Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett. 258:286–290. 2007. View Article : Google Scholar : PubMed/NCBI

25 

Yang Z, Wang Z, Fan Y, et al: Expression of CD133 in SW620 colorectal cancer cells is modulated by the microenvironment. Oncol Lett. 4:75–79. 2012.PubMed/NCBI

26 

Sutherland RM: Cell and environment interactions in tumor microregions: the multicell spheroid model. Science. 240:177–184. 1988. View Article : Google Scholar : PubMed/NCBI

27 

Freyer JP, Tustanoff E, Franko AJ, et al: In situ oxygen consumption rates of cells in V-79 multicellular spheroids during growth. J Cell Physiol. 118:53–61. 1984. View Article : Google Scholar : PubMed/NCBI

28 

Freyer JP and Sutherland RM: A reduction in the in situ rates of oxygen and glucose consumption of cells in EMT6/Ro spheroids during growth. J Cell Physiol. 124:516–524. 1985. View Article : Google Scholar : PubMed/NCBI

29 

Kemper K, Sprick MR, de Bree M, et al: The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 70:719–729. 2010. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Ohnishi K, Tani T, Bando S, Kubota N, Fujii Y, Hatano O and Harada H: Plastic induction of CD133AC133-positive cells in the microenvironment of glioblastoma spheroids. Int J Oncol 45: 581-586, 2014.
APA
Ohnishi, K., Tani, T., Bando, S., Kubota, N., Fujii, Y., Hatano, O., & Harada, H. (2014). Plastic induction of CD133AC133-positive cells in the microenvironment of glioblastoma spheroids. International Journal of Oncology, 45, 581-586. https://doi.org/10.3892/ijo.2014.2483
MLA
Ohnishi, K., Tani, T., Bando, S., Kubota, N., Fujii, Y., Hatano, O., Harada, H."Plastic induction of CD133AC133-positive cells in the microenvironment of glioblastoma spheroids". International Journal of Oncology 45.2 (2014): 581-586.
Chicago
Ohnishi, K., Tani, T., Bando, S., Kubota, N., Fujii, Y., Hatano, O., Harada, H."Plastic induction of CD133AC133-positive cells in the microenvironment of glioblastoma spheroids". International Journal of Oncology 45, no. 2 (2014): 581-586. https://doi.org/10.3892/ijo.2014.2483
Copy and paste a formatted citation
x
Spandidos Publications style
Ohnishi K, Tani T, Bando S, Kubota N, Fujii Y, Hatano O and Harada H: Plastic induction of CD133AC133-positive cells in the microenvironment of glioblastoma spheroids. Int J Oncol 45: 581-586, 2014.
APA
Ohnishi, K., Tani, T., Bando, S., Kubota, N., Fujii, Y., Hatano, O., & Harada, H. (2014). Plastic induction of CD133AC133-positive cells in the microenvironment of glioblastoma spheroids. International Journal of Oncology, 45, 581-586. https://doi.org/10.3892/ijo.2014.2483
MLA
Ohnishi, K., Tani, T., Bando, S., Kubota, N., Fujii, Y., Hatano, O., Harada, H."Plastic induction of CD133AC133-positive cells in the microenvironment of glioblastoma spheroids". International Journal of Oncology 45.2 (2014): 581-586.
Chicago
Ohnishi, K., Tani, T., Bando, S., Kubota, N., Fujii, Y., Hatano, O., Harada, H."Plastic induction of CD133AC133-positive cells in the microenvironment of glioblastoma spheroids". International Journal of Oncology 45, no. 2 (2014): 581-586. https://doi.org/10.3892/ijo.2014.2483
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team